Novo Nordisk A/S

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen Other stock markets 11:20:00 2025-06-20 am EDT			5-day change	1st Jan Change
475.80 ^DKK	-2.58%		-7.83%	-23.77%

10:38am	US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list	RE
10:37am	US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list	RE

NOVO NORDISK : Largest shareholder in action

Published on 05/19/2025 at 07:36

This Alphavalue article, the European leader in independent research, is only available to subscribers .

Alphavalue is exclusively on MarketScreener.
To unlock the article, SUBSCRIBE!

Already a customer? Log In

Latest news about Novo Nordisk A/S

US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list	10:38am	RE
US judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list	10:37am	RE
NOVO NORDISK : Buy rating from UBS	10:07am	ZD
Eli Lilly says India response to obesity drug Mounjaro is 'positive', will focus on meeting demand	04:52am	RE
United Laboratories International Says United Biotechnology Got Upfront Payment From Novo Nordisk	04:20am	RE
United Laboratories Unit Gets $180 Million Upfront Payment from Novo Nordisk	03:09am	MT
European shares fall as Middle East tensions weigh; eyes on Fed decision	Jun. 18	RE
Scholar Rock's drug helps Zepbound patients retain more muscle in trial	Jun. 18	RE
U.S. judge upholds FDA's removal of Ozempic, Wegovy from drug shortage list	Jun. 18	RE
Fat, not muscle: Drugmakers in race for next weight-loss breakthrough	Jun. 18	RE
Health Rounds: Weight-loss surgery more effective than drugs in real world study	Jun. 18	RE
WeightWatchers to exit process to cut $1.15 billion debt next week	Jun. 17	RE
Mark Cuban's Cost Plus partners with telehealth firm to offer employers obesity care drugs	Jun. 17	RE
Trump Administration to Consider Pharma Advertising Crackdown	Jun. 17	MT
Trump Administration to Consider Pharma Advertising Crackdown, Bloomberg reports	Jun. 17	MT
NOVO NORDISK : UBS reiterates its Buy rating	Jun. 17	ZD
Lannebo Mixfond Offensiv increased by 2.6 percent in May – reduced exposure to cyclical industries	Jun. 17	FW
Lilly will offer higher doses of Zepbound on its website	Jun. 16	RE
European shares snap five-day losing streak	Jun. 16	RE
European Equities Traded in the US as American Depositary Receipts Rise in Monday Trading	Jun. 16	MT
Lilly to offer highest doses of weight-loss drug Zepbound on website	Jun. 16	RE
NOVO NORDISK : Gets a Buy rating from JP Morgan	Jun. 16	ZD
JP Morgan lowers target price for Novo Nordisk to 650 Danish kroner (1,000), reiterates overweight rating - BN	Jun. 16	FW
Eli Lilly's experimental obesity drug shows over 11% weight loss in early trial	Jun. 13	RE
Global markets live: Tesla, Google, Apple, Novo Nordisk, Boeing…	Jun. 13

Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (93.6%); - rare disease treatment products (6.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (20.8%), the United States (57.6%), North America (3.7%), China (6.4%) and other (11.5%).

Employees

77,406

Sector

Pharmaceuticals

Calendar

03:45pm - American Diabetes Association Scientific Conference - Oral Presentation: 86-OR

More about the company